Rolando Vega

The shift towards patient-centric, self-administered, and at-home therapies is fundamentally transforming the pharmaceutical landscape and, in turn, redefining the role of contract development and manufacturing organisations CDMOs. Drug delivery systems and combination products are no longer viewed as peripheral add-ons; they have become critical strategic assets that demand seamless integration across formulation, device engineering, and manufacturing disciplines.

For the pharma contract manufacturing sector, this evolution presents both a challenge and an opportunity. CDMOs must adapt to manage the increasing technical, regulatory, and operational complexities associated with combination products while offering the flexibility, expertise, and innovation that pharma sponsors now require.

This session will examine how delivery technologies are reshaping the relationship between pharmaceutical companies and their contract manufacturing partners, highlighting the need for early collaboration, robust supply chain strategies, and co-development models that align with patient-centric outcomes.

Key Discussion Points:

• How combination products are transforming the CDMO value proposition.
• Integrating drug, device, and packaging manufacturing within a unified operational framework.
• Building agile, end-to-end partnerships to support faster market access and lifecycle management.